

VARIAN MEDICAL SYSTEMS INC  
Form 8-K  
December 21, 2017

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **December 16, 2017**

**VARIAN MEDICAL SYSTEMS, INC.**

(Exact name of registrant as specified in its charter)

|                              |                  |                   |
|------------------------------|------------------|-------------------|
| <b>Delaware</b>              | <b>1-7598</b>    | <b>94-2359345</b> |
| (State or other jurisdiction | (Commission File | (I.R.S.           |
| of incorporation)            | Number)          | Employer          |
|                              |                  | Identification    |
|                              |                  | No.)              |

**3100 Hansen Way, Palo Alto, CA 94304-1030**

(Address of principal executive offices, including zip code)

**(650) 493-4000**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On December 16, 2017, Mark R. Laret notified Varian Medical Systems, Inc. (the “**Company**”) of his decision not to stand for re-election to the Company’s Board of Directors (the “**Board**”) at the Company’s 2018 Annual Meeting of Stockholders, which will be held on February 8, 2018. Mr. Laret’s decision not to stand for re-election to the Board is not due to any disagreement with the Company, including with respect to any matter relating to the Company’s operations, policies or practices.

Mr. Laret has served as a member of the Board for over ten years and as Chairman of the Nominating and Governance Committee for about eight years. The Company and the Board are grateful to Mr. Laret for his distinguished Board service and leadership as Chairman of the Nominating and Governance Committee.

**SIGNATURE(S)**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Varian Medical Systems, Inc.

By: /s/ John W. Kuo

Name: John W. Kuo

Title: Senior Vice President, General Counsel and  
Corporate Secretary

Dated: December 21, 2017